Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - palbociclib - capsule - 100mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - palbociclib - capsule - 125mg

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 100mg - capsule - 100 mg - active: palbociclib 100mg excipient: colloidal silicon dioxide gelatin   iron oxide red   iron oxide yellow   lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide   - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 125mg - capsule - 125 mg - active: palbociclib 125mg excipient: colloidal silicon dioxide gelatin   iron oxide red   iron oxide yellow   lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide   - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 75mg - capsule - 75 mg - active: palbociclib 75mg excipient: colloidal silicon dioxide gelatin   iron oxide red   iron oxide yellow   lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide   - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

Կանադա - անգլերեն - Health Canada

pfizer canada ulc - palbociclib - capsule - 75mg - palbociclib 75mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

pfizer canada ulc - palbociclib - capsule - 100mg - palbociclib 100mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

pfizer canada ulc - palbociclib - capsule - 125mg - palbociclib 125mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

pfizer canada ulc - palbociclib - tablet - 75mg - palbociclib 75mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

pfizer canada ulc - palbociclib - tablet - 100mg - palbociclib 100mg - antineoplastic agents